Rapid Briefs
VV catches the signal early, explains it cleanly, shows the source trail, and tells you what not to overclaim.
Filtered signal trail
Penn Medicine reports decade-long follow-up from one of the earliest CAR-T lymphoma trials, with some patients alive without relapse after a single infusion.
Why now
Long-term follow-up turns early CAR-T enthusiasm into a decade-scale remission signal for some patients.
Across leukemia, lupus, kidney transplant desensitization, and solid tumor approval, CAR-T is showing up as a broader platform, not just a blood-cancer treatment.
Why now
Several CAR-T stories are clustering at once across patient care, autoimmune disease, transplant access, and solid-tumor approval.
Satri-cel crossed a historic regulatory line in stomach cancer, but the approval is limited to China and a specific advanced cancer indication.
Why now
CAR-T has moved beyond blood-cancer approvals and into its first approved solid-tumor indication.
